KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Investment Securities (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 14 years of Gains from Investment Securities data on record, last reported at $77.5 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 24119.38% year-over-year to $77.5 million; the TTM value through Dec 2025 reached $86.9 million, changed N/A, while the annual FY2025 figure was $86.9 million, N/A changed from the prior year.
  • Gains from Investment Securities reached $77.5 million in Q4 2025 per IONS's latest filing, up from $9.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $77.5 million in Q4 2025 and bottomed at -$15.8 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $5.7 million, with a median of $389000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: tumbled 5390.0% in 2023, then surged 24119.38% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $16.7 million in 2021, then plummeted by 38.44% to $10.3 million in 2022, then tumbled by 86.12% to $1.4 million in 2023, then tumbled by 77.61% to $320000.0 in 2024, then soared by 24119.38% to $77.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $77.5 million in Q4 2025, $9.8 million in Q3 2025, and $17000.0 in Q2 2025.